Study Shows Mannatech's Ambrotose Complex Improves Well-Being in
COPPELL, Texas, Oct 04, 2011 (BUSINESS WIRE) --
Mannatech, Incorporated(NASDAQ: MTEX), the leading innovator and provider of nutritional supplements and skin care products based on Real Food Technology(R) solutions, announced findings today from a randomized, double-blind, placebo-controlled trial involving more than 100 healthy adults and its Ambrotose(R) complexpowder.
The study compared the adults who consumed Ambrotose to those who consumed a placebo, and individuals who consumed the complex powder reported numerous health and well-being benefits following 12 weeks of intake. The study, conducted by Dr. Talitha Best and colleagues in Australia, was published in the peer-reviewed journal Applied Research in Quality of Life.
"Dr. Best has been committed to investigating the impact of plant saccharides, including Mannatech's Ambrotose complex, on brain function for more than six years," said Dr. Robert Sinnott, co-CEO and chief science officer of Mannatech. "In this blinded study, healthy adults taking Ambrotose complex powder perceived numerous quality-of-life benefits, including some that have been confirmed by formal cognitive testing (1)+,(2)+*. Because our preclinical research suggests the product also provides gastrointestinal benefits, we were pleased that gastrointestinal effects were among the perceived benefits reported by individuals who consumed Ambrotose complex."
The Australian government recently awarded Dr. Best a 12-month Researchers in Business (RiB) grant to help develop research on Mannatech's glyconutritional products and to promote Australian research innovation. The $10 million RiB program is part of Enterprise Connect, an initiative within the Australian government's Department of Innovation, Industry, Science and Research. The program is designed to accelerate industry innovation and competitiveness by connecting university and public agency researchers with businesses that wish to develop new ideas with commercial potential.
Dr. Best, who conducted the study with Associate Professor Eva Kemps, Flinders University, and Dr. Janet Bryan, University of South Australia (UniSA), is a post-doctoral research fellow at the Nutritional Physiology Research Centre, UNiSA, and the Brain Sciences Institute, Swinburne University of Technology.
Individuals interested in Mannatech's products or exploring its business opportunity are encouraged to learn more at Mannatech.com.
Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech's proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea and Mexico. For more information, visit Mannatech.com.
Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
+Mannatech provided the Ambrotose supplement and placebo used in this study.
+Mannatech provided partial funding and provided the Ambrotose supplement and placebo used in this study.
1. Best T, Kemps E, Bryan J. Saccharide effects on cognition and well-being in middle-aged adults: A randomized controlled trial. Dev Neuropsych 2010;35:66-80.
2. Best T, Howe P, Bryan J, Buckley J, Scholey A. Plant polysaccharides, memory and cognition in middle-aged adults. Presented at the 38th Australasian Experimental Psychology Conference in Aukland, New Zealand, April 28-30, 2011.
* These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: Mannatech, Incorporated
for Mannatech, Incorporated
Shawn Paul Wood, 972-499-6614